Zealand Entered into a License and Development Agreement with Novo Nordisk for Zegalogue (dasiglucagon) to Treat Diabetes
Shots:
- Zealand to receive $3.32M up front, ~$5.9M in near-term development, regulatory and manufacturing-based milestones & is also eligible to receive ~$29.29M in sales-based milestones along with royalties on global net sales of Zegalogue to be marketed by Novo Nordisk
- Zealand will lead the planned regulatory, development, and manufacturing activities to support the development and approval outside of the US for the treatment of diabetes who experienced severe hypoglycemic episodes. Zealand also obtains all non-licensed IP rights to other dasiglucagon development programs
- The acquisition marks further execution of Zealand’s strategy to establish commercial partnerships to develop innovative peptide therapeutics. Zegalogue has been approved in the US for sev. hypoglycemia in pediatric & adult patients with diabetes aged ≥6yrs.
Ref: GlobeNewswire | Image: Zealand
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
